Brief: Clover Biopharmaceuticals Enters Exclusive Agreement With Adimmune Corporation
20/02/2023 01:30
Feb 20 (Reuters) - Clover Biopharmaceuticals Ltd
2197.HK :
* ENTERED EXCLUSIVE AGREEMENT WITH ADIMMUNE CORPORATION
* AGREEMENT FOR CLOVER TO DISTRIBUTE ADIMFLU-S (QIS) IN
MAINLAND
CHINA
* UNDER TERMS OF EXCLUSIVE AGREEMENT, CO GAINS COMMERCIAL
RIGHTS
TO ADIMFLU-S (QIS) IN CHINA, BANGLADESH, BRAZIL, PHILIPPINES
Further company coverage: 2197.HK
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune